These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23343250)

  • 41. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
    Theriou C; Fielden CA; Kitterick PT
    Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Utility Analysis of Single-Fraction Versus Multiple-Fraction Radiotherapy in Patients with Painful Bone Metastases: An Iranian Patient's Perspective Study.
    Bayazidi Y; Keshtkaran A; Homaie Rad E; Ansari M; Javanbakht M; Hashemi Meshkini A; Nikfar S; Zaboli P
    Value Health Reg Issues; 2017 May; 12():84-89. PubMed ID: 28648321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
    Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
    Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling.
    Neumann A; Schwarz P; Lindholm L
    Cost Eff Resour Alloc; 2011 Nov; 9(1):17. PubMed ID: 22099547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.
    Retèl VP; van der Molen L; Hilgers FJ; Rasch CR; L'Ortye AA; Steuten LM; van Harten WH
    BMC Cancer; 2011 Nov; 11():475. PubMed ID: 22051143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Day care versus inpatient management of nausea and vomiting of pregnancy: cost utility analysis of a randomised controlled trial.
    Murphy A; McCarthy FP; McElroy B; Khashan AS; Spillane N; Marchocki Z; Sarkar RK; Higgins JR
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():78-82. PubMed ID: 26708475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain.
    Kumar K; Rizvi S
    Pain Med; 2013 Nov; 14(11):1631-49. PubMed ID: 23710759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
    Wali AR; Park CC; Brown JM; Mandeville R
    Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.
    Comay D; Blackhouse G; Goeree R; Armstrong D; Marshall JK
    Can J Gastroenterol; 2007 Apr; 21(4):217-22. PubMed ID: 17431509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
    Martikainen JA; Kivioja A; Hallinen T; Vihinen P
    Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm.
    Ehlers L; Overvad K; Sørensen J; Christensen S; Bech M; Kjølby M
    BMJ; 2009 Jun; 338():b2243. PubMed ID: 19553267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis.
    Perez A; Touchette DR; DiDomenico RJ; Stamos TD; Walton SM
    Pharmacotherapy; 2011 Jun; 31(6):552-65. PubMed ID: 21923439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving Maternal Care through a State-Wide Health Insurance Program: A Cost and Cost-Effectiveness Study in Rural Nigeria.
    Gomez GB; Foster N; Brals D; Nelissen HE; Bolarinwa OA; Hendriks ME; Boers AC; van Eck D; Rosendaal N; Adenusi P; Agbede K; Akande TM; Boele van Hensbroek M; Wit FW; Hankins CA; Schultsz C
    PLoS One; 2015; 10(9):e0139048. PubMed ID: 26413788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.
    Yu J; Smith KJ; Brixner DI
    CNS Drugs; 2010 Aug; 24(8):695-712. PubMed ID: 20658800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.